Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Clinical Trial ID NCT01986881

PubWeight™ 10.86^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01986881

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.	Diab Vasc Dis Res	2015	1.73
2	Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.	Drug Des Devel Ther	2014	1.14
3	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).	Cardiovasc Diabetol	2014	1.12
4	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.	Diabetes Metab Syndr Obes	2014	1.05
5	SLC transporters as therapeutic targets: emerging opportunities.	Nat Rev Drug Discov	2015	1.02
6	The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.	Int J Clin Pract	2015	0.79
7	Current perspectives on cardiovascular outcome trials in diabetes.	Cardiovasc Diabetol	2016	0.79
8	Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.	Cardiovasc Diabetol	2016	0.76
9	Cardiovascular effects of anti-diabetes drugs.	Expert Opin Drug Saf	2016	0.75
10	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.	Herz	2016	0.75
11	Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.	Vasc Health Risk Manag	2016	0.75
12	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.	Clin Pharmacol Ther	2015	0.75